본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

초록보기

Objective: Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease. Both tralokinumab and dupilumab have been recommended in the European Guideline for the treatment of adult patients with severe AD. In Korea, dupilumab has been approved for patients with moderate to severe AD, and reimbursed for those with severe AD. Since there is no clinical trial directly comparing tralokinumab and dupilumab, we conducted indirect comparison to assess the clinical usefulness in patients with AD. Methods: We selected clinical trials for indirect comparison through a systematic literature review. Individual patient data were available for the tralokinumab clinical trial, and aggregated data were available for the dupilumab clinical trial. Therefore, we employed the Matching-Adjusted Indirect Comparison (MAIC) method. The treatment efficacy was assessed based on whether patients achieved a 75% reduction on the Eczema Area and Severity Index (EASI 75) after drug administration. Results: The difference in the proportion of patients achieving EASI 75 between tralokinumab and dupilumab was 4.7% (95% CI: −7.9 to 17.3). Considering the non-inferiority margin for the EASI 75 achievement rate is −10%, tralokinumab is deemed non-inferior to dupilumab as the lower bound of the CI for the difference in the EASI 75 achievement rate between tralokinumab and dupilumab was within −10%. Conclusion: We conducted a MAIC analysis comparing tralokinumab and dupilumab based on EASI 75 achievement. The findings of this study show that tralokinumab is non-inferior to dupilumab and can be implemented in Korean clinical settings with a therapeutic position comparable to dupilumab.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
양극성 장애의 약물치료 가이드라인 비교 = Comparative review of pharmacological treatment guidelines for bipolar disorder 진서연, 김효영, 김예슬, 허채원, 권보영, 최보윤, 이보배, 이지예, 권채은, 문영도, Kaveesha, Fernando, 박지현 p. 153-167

Therapeutic duplication as a medication error risk in fixed-dose combination drugs for dyslipidemia : a nationwide study Wonbin Choi, Hyunji Koo, Kyeong Hye Jeong, Eunyoung Kim, Seung-Hun You, Min-Taek Lee, Sun-Young Jung p. 168-177

트랄로키누맙과 두필루맙의 매칭 조정 간접 비교 = Matching-adjusted indirect comparison (MAIC) of tralokinumab versus dupilumab for the treatment of moderate to severe adult atopic dermatitis 김태경, 신근수, 김효진, 김유진, 최이정, 이동훈 p. 178-185

국내 약학대학 학생들의 보건의료전문직간 교육에 대한 인식 = Pharmacy school students’ perceptions of interprofessional education 박한슬, 강현아, 김현진, 심미경, 손현순 p. 186-194

Hematocrit determination using a volumetric absorptive microsampling technique in patients with pancreatic cancer Yeolmae Jung, Seunghyun Yoo, Minseo Kang, Hayun Lim, Myeong Hwan Lee, Ji Kon Ryu, Jangik Lee p. 195-201

블렌디드 러닝을 활용한 팀 기반 학습 실습 수업에서 약학대학 학생의 학습만족도와 플랫폼 선호도 = Effects of blended learning on pharmacy student learning satisfaction and learning platform preferences in a team-based learning pharmacy experiential course : a pilot study : 예비 연구 김소원, 최은주, 이윤정 p. 202-209

참고문헌 (19건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Comparative Effectiveness Without Head-to-Head Trials 미소장
2 The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials 미소장
3 The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants 미소장
4 Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research 미소장
5 Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t 미소장
6 Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis 미소장
7 2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity 미소장
8 Alternative weighting schemes when performing matching‐adjusted indirect comparisons 미소장
9 A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC 미소장
10 Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis 미소장
11 Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis 미소장
12 Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)* 미소장
13 Interpretation of EASI-75 from a patient perspective—A post hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis 미소장
14 Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations 미소장
15 Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis 미소장
16 Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial 미소장
17 The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis 미소장
18 European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy 미소장
19 Non‐biologic systemic treatments for atopic dermatitis: Current state of the art and future directions 미소장